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Simple Summary: The Tribbles family of pseudokinases controls a wide number of processes during
cancer on-set and progression. However, the exact contribution of each of the three family members
is still to be defined. Their functions appear to be context-dependent as they can act as oncogenes or
tumor suppressor genes. They act as scaffolds modulating the activity of several signaling pathways
involved in different cellular processes. In this review, we discuss the state-of-knowledge for TRIB1,
TRIB2 and TRIB3 in the development and progression of colorectal cancer. We take a perspective
look at the role of Tribbles proteins as potential biomarkers and therapeutic targets.
Abstract: The Tribbles family of pseudokinases controls a wide number of processes during cancer
on-set and progression. However, the exact contribution of each of the three family members is
still to be defined. Their function appears to be context-dependent as they can act as oncogenes or
tumor suppressor genes. They act as scaffolds modulating the activity of several signaling pathways
involved in different cellular processes. In this review, we discuss the state-of-knowledge for TRIB1,
TRIB2 and TRIB3 in the development and progression of colorectal cancer. We take a perspective
look at the role of Tribbles proteins as potential biomarkers and therapeutic targets. Specifically,
we chronologically systematized all available articles since 2003 until 2020, for which Tribbles were
associated with colorectal cancer human samples or cell lines. Herein, we discuss: (1) Tribbles
amplification and overexpression; (2) the clinical significance of Tribbles overexpression; (3) upstream
Tribbles gene and protein expression regulation; (4) Tribbles pharmacological modulation; (5) genetic
modulation of Tribbles; and (6) downstream mechanisms regulated by Tribbles; establishing a
comprehensive timeline, essential to better consolidate the current knowledge of Tribbles’ role in
colorectal cancer.
Keywords: tribbles; colon cancer; oncogene; colorectal cancer; pseudokinase; biomarker; gene
expression; genomic amplification; pharmacological target
1. Introduction
Colorectal cancer (CRC) refers to a malignant tumor that arises from the colon or
rectum epithelium. They are often referred together due to their many features in common.
Worldwide, CRC was the third most common malignancy (1,931,590 cases; 10%) and the
second most frequent cause of cancer deaths (935,173 cases; 9.4%), in both genders and
all ages, in 2020 [1]. The fact that mortality is approximately half the incidence suggests a
relatively good prognosis, which is closely related to improvements in cancer treatment
and management. Since survival is highly dependent on the stage of cancer at diagnosis,
early detection stands out as one of the best prognosis factors. The majority of cases of this
highly heterogeneous disease appear between 50 and 75 years old, being more frequent in
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men than in women [2]. Risk factors are still unclear, but evidence supports the association
of poor diet, lack of physical activity, smoking and an increasing prevalence of overweight,
obesity, and type 2 diabetes with CRC [2].
Sporadic cases are the majority of CRC, while germline mutations and hereditary syn-
dromes account for only 6 to 10% of all cases [3]. Two molecular pathways are traditionally
associated with sporadic CRC: the adenoma–carcinoma, or chromosomal instability, path-
way (70–75%), and the serrated pathway (25–30%) [2]. In the adenoma–carcinoma pathway,
CRC evolves from non-malignant precursor lesions called adenomas, for a period of at
least 10 years [4]. This process begins with the activation of Wnt signaling due to the loss of
the tumor suppressor APC (Adenomatous polyposis coli) through inactivating mutations.
Over the years, a series of mutations start to accumulate. KRAS oncogene mutation arises
preferentially in early steps, while TP53, SMAD4, PIK3C, and PTEN mutations occur at
later phases [5]. For the serrated pathway, the earliest event on sessile serrated adenomas
is thought to be the activation of the MAPK pathway through BRAF oncogene mutation
leading to a global methylation of CpG islands and consequently silencing of the mismatch
repair gene MLH1 or the cyclin-dependent kinase inhibitor p16. In traditional serrated
adenomas that comprise less than 1% of all serrated lesions, MAPK pathway activation is
more frequently associated with mutation of the KRAS oncogene, although BRAF mutation
may also occur [6,7].
Although driver mutations are recognized, over time several of these pathways may
overlap or interact. Upon Wnt activation, β-catenin accumulates and translocates into
the nucleus where it binds TCF4 to promote the transcription of Jun, c-Myc or CyclinD-1,
promoting tumor progression. On the other hand, APC mutation promotes Wnt signal
transduction by stabilization of β-catenin [8–10]. Overexpression of amplified genes like
MYC and MET can also occur through double minute (DM) chromosomes (round-circle,
acentric double-strand extra-chromosome DNA that usually exist in pairs). The formation
of DM chromosomes is usually regarded as an important sign of genome instability and
occurs in 2.6% of CRC [11,12].
As increased EGFR expression has been observed during colorectal carcinogenesis,
targeted therapies with monoclonal antibodies such as cetuximab and panitumumab which
prevent EGFR activation are commonly used in late-stage CRC. However, mutations in
KRAS, NRAS, and BRAF, and amplification of ERBB2 and MET, represent mechanisms
of primary and secondary resistance to anti-EGFR therapy. In fact, only patients with
wild-type RAS benefit from anti-EGFR therapy. Nonetheless, RAS-BRAF wild type CRC
is also associated with resistance to anti-EGFR treatment in the presence of high c-MYC
levels [13–16]. Targeting specific signaling pathways using multiple agents is the best
option to achieve a better therapeutic outcome. Clinical trials have shown promising
results with a combination of bevacizumab, a monoclonal antibody that inhibits VEGF,
and the EGFR inhibitor erlotinib, that blocks these two important pathways in cancer
growth [17].
Molecular characterization of CRC can guide therapeutic decisions or define patient
prognosis. In fact, a classification based on four consensus molecular subtypes (CMSs)
was established: (1) CMS1, associated with hypermutations, microsatellite instability and
strong immune activation; (2) CMS2, the canonical subtype, characterized by an epithelial
phenotype and increased WNT and MYC activation; (3) CMS3, characterized by metabolic
dysregulation; (4) CMS4, which shows prominent transforming growth factor–β (TGFβ)
activation, stromal invasion, and increasing angiogenesis [18]. Nonetheless, TNM staging
remains the standard for clinical decision-making. In stage I and II, the disease is located in
the colon or rectum, in stage III there is ganglionic spread and in stage IV there is already the
presence of distant metastasis usually liver and lung [19]. Surgery is the optimal primary
treatment for CRC and should be preceded by neoadjuvant radiotherapy. Chemotherapy
can also be used in combination with radiotherapy for neoadjuvant treatment. Recurrence
and metastatic patterns differ between colon and rectal cancers. Nevertheless, patient’s
survival with metastatic CRC varies from 5 to 19 months, depending on disease stage. There
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is a clear need for new biomarkers predicting CRC behavior and innovative therapeutic
targets [20,21].
Tribbles pseudokinase family members (TRIB1 (C8FW or SKIP1), TRIB2 (C5FW) and
TRIB3 (NIPK, SKIP3 or LKW)) might be biomarkers of interest in colorectal cancer. TRIB1
lacks, while TRIB2 and TRIB3 have low, affinity for ATP, along with residual phospho-
transferase capacity [22]. Instead of phosphorylating target proteins, they function as
protein scaffolds that modulate diverse signaling cascades involved in proliferation, sur-
vival, differentiation and drug resistance [23]. Tribbles can lead to protein degradation by
binding to ubiquitin ligases promoting the ubiquitylation of substrates [24], stabilization by
suppressing sumoylation [25], or affecting signal transduction pathways through binding
of signaling molecules like MEK and AKT [26]. For example, TRIB2 has been previously
identified as an oncoprotein that contributes to the pathogenesis of acute myelogenous
leukemia (AML) through the inhibition of C/EBPα function, similarly to slbo inactivation
by Drosophila Tribbles [27]. Different reports show that Tribbles proteins exert a role in the
development of different types of tumors. However, they might exhibit an oncogenic or
tumor suppressive behavior depending on the family member and cellular context [28].
For instance, TRIB2 promoted AKT activation and, consequently, the inactivation of the
transcription factor FOXO in melanoma. Expression of FOXO target genes, which can
induce apoptosis, are therefore attenuated by TRIB2 overexpression [29,30]. By contrast,
TRIB3 was shown to have the opposite effect [31], and its loss was associated with a more
aggressive tumor phenotype [32]. Increased levels of TRIB3 inhibited AKT activity and
consequently induced cell death via FOXO in glioma cells [33]. These data support a
scenario in which the balance between the expression of Tribbles might determine tumor
progression, in this particular case through FOXO proteins activity via AKT. Several studies
have been published reporting the role of Tribbles proteins in different types of cancer,
including TRIB1 in prostate [34], glioma [35], ovarian [36], and thyroid [37] cancers; TRIB2
in melanoma [38], lung [39], liver [40–42], acute leukemias [27,43,44], and glioblastoma [45];
and TRIB3 in lung [46], breast [47,48], renal [49], gastric [50], liver [51], retinoblastoma [52],
glioblastoma [53], and ovarian [54] cancers; as well as all Tribbles members in colorectal
cancer, as herein fully presented. Tribbles pseudokinases may have an immediate impact
in cancer treatment being potential therapeutic targets.
With this review, we established a comprehensive timeline describing what is known
about the putative role of each Tribble family member in the development of colorectal
cancer (Figure 1). This document should also serve as a guide for future research, describing
the available bioinformatic datasets regarding colorectal cancer studies.
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me ber (TRIB1 in grey flag, TRIB2 in red flag, and TRIB3 i blue flag). First author last name is shown for each flag. A total
of four articles studying or including TRIB1, five for TRIB2, and 14 for TRIB3, in colon cancer, were identified from 2003 to
2020 and are included in the review.
Cancers 2021, 13, 2825 4 of 19
2. Tribbles Amplification and Overexpression in Colon Cancer Tissues
The identification of increased genomic copy number (genomic amplification) in
chromosome 8, combined with altered gene expression (up-regulation), allowed the first
identification of TRIB1 as a putative biologically relevant oncogene, in primary colorectal
tumor or established colorectal cancer (CRC) cells lines containing the amplicon [55]. Half
a decade later, a study published in 2014, identified TRIB1 as a double minute (DM)-carried
gene in a human CRC cell line [56,57]. DMs are small-paired, autonomously replicating,
extrachromosomal DNA segments that contain amplified oncogenes, mainly present in
solid tumors and identified in many human cancer cell lines [58]. Indeed, along with MYC
and FGFR2 (among others), TRIB1 was amplified in NCI-H716 cells compared to normal
human peripheral blood DNA. Though the authors also showed elevated TRIB1 mRNA
levels in CRC cells, it was compared to non-paired normal colon tissue [56]. In a different
study, TRIB1 region was amplified in 7 out of the 15 CRC cell lines tested. TRIB1 was
clearly amplified and very highly expressed in NCI-H716 cells. However, there was no
correlation between DNA copy number of the TRIB1 region (Chr8: 126,393,571–126,567,050)
and TRIB1 protein. The authors did find a weak correlation between TRIB1 copy number
and mRNA expression [59]. They also found that TRIB1 copy number was gained in 11%
of primary CRC samples (n = 881 patients’ cohort, Oncomine database). From a different
cohort, 11 tumors (14.4% out of 76 cases) were TRIB1-amplified; this value was above
MYC amplification, for which only 6 tumors were amplified (7.4%) [59]. It was not until
2017 that the TRIB1 gene was shown to be amplified and overexpressed in CRC tissues,
when compared with paired surrounding non-tumor tissues from the same patients [60].
By using the TCGA database, the authors described that the copy number of TRIB1 in
human CRC tissues (n = 212) was significantly increased, when compared with normal
colon tissues (n = 79). Data available from the Gene Expression Omnibus (GEO) [61],
revealed that TRIB1 gene expression levels in CRC tissues were elevated, compared with
normal colon tissues (microarray expression studies from Oncomine) [60]. The authors
experimentally validated the data by western blotting and found that the levels of TRIB1
protein were elevated in 6 out of 8 (75%) CRC tumors when compared to matched adjacent
non-tumor tissue. In addition, TRIB1 protein overexpression was detected in 52 out of 75
(69.3%) of CRC cases as assessed by immunohistochemistry (IHC) compared with matched
normal tissue [60].
The first hint that TRIB2 expression was related to colon cancer was reported in
2013, when TRIB2 protein was detected in CRC samples using tissue microarray analysis
(TMA) by IHC [41]. Later in 2017, TRIB2 mRNA and protein expression were found to be
significantly increased in primary colon cancer tissue samples when compared to matched
normal tissue samples [30]. However, none of these studies specifically focused on TRIB2
in colon cancer. One year later, it was further confirmed that TRIB2 was overexpressed in
colorectal cancer patients, in primary tumor samples obtained from surgical resection, prior
to receiving any kind of chemotherapy or radiotherapy [62]. The authors included an initial
GEO database analysis, and found that TRIB2 was highly expressed in primary tumor
tissues compared with adjacent normal tissues [62]. These data have been experimentally
validated by RT-PCR, showing that TRIB2 gene expression was higher in a great proportion
of tumors (73.3%), when compared to adjacent tissues. Accordingly, IHC staining showed
that the average expression level of TRIB2 was elevated in CRC tissues compared with
normal tissues. Further paired analysis also demonstrated that TRIB2 protein level was
higher in tumors (76.7%) [62]. All these findings suggest that TRIB2 is highly expressed in
a large subset of CRC patients.
Though initially stated as “data not shown”, the very first input on TRIB3 gene overex-
pression in colon tumor samples, when compared to matched normal colon samples, was
published in 2003 [63], much earlier than the other two Tribbles family members (Figure 1).
The authors had identified SKIP3, a protein with very high homology to other previously
reported mammalian orthologs of Drosophila tribbles [63], later named TRIB3. While in the
normal tissues tested (including colon), TRIB3 mRNA levels were preferably elevated in
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liver, the highest expression was observed in tumor-derived cell lines, which included the
colorectal adenocarcinoma SW480 cells [63]. TRIB3 transcript levels were increased in colon
adenocarcinoma samples, when compared to normal human tissues. Its tumor-specific lo-
calization was further confirmed by in situ hybridization [63]. In human tumor xenografts
with HT-29 colorectal adenocarcinoma cells, TRIB3 expression pattern was proximal to a
region of cell death, localized to a periapoptotic region. Nonetheless, its localization did not
correlate with cell proliferation nor with cells undertaking apoptosis [63]. The following
year, another article showed elevated gene expression of TRIB3 in different tumor cell
lines [64]. In agreement with the previous report [63], one of the strongest signals was
observed in the colorectal adenocarcinoma cell line SW480 [64]. Although not shown, the
authors described a significant higher TRIB3 gene expression in colon-carcinoma compared
to the corresponding normal tissues. Moreover, they also observed up to 400-fold over-
expression of TRIB3 mRNA in human tumor tissues from primary tumors with different
TNM stages versus normal colonic mucosa [64]. In 2007, a study on the TRIB3 putative
role in tumorigenesis, included the analysis of TRIB3 mRNA expression level in different
carcinomas [65]. TRIB3 was highly expressed in colon tumor tissues, moderately in lung
and esophageal, very limited in stomach, but not increased in liver or kidney cancers [65].
Interestingly, the authors discovered that TRIB3 was overexpressed in all the colon cancer
tissue pairs analyzed [65]. Consolidating the results described in previous studies for
SW480 cells [63,64], it was shown that all other gastrointestinal cell lines tested (Caco2,
DLD-1, LoVo, HCT116, HT-29, and KM12SM) expressed TRIB3 gene [66]. Moreover, almost
90% of primary CRC samples analyzed had higher levels of TRIB3 mRNA in tumors,
compared to the paired normal regions [66]. TRIB3 protein localized both in the nucleus
and the cytoplasm of epithelial cells, while very weakly detectable in stromal cells [66].
The expression of TRIB3 protein was positively correlated with its mRNA expression,
though not all of the analyzed cases showed higher TRIB3 levels in tumor regions than
in normal regions [66]. Consistently with previous results herein described for colon, but
not concerning liver [65], an additional report showed high levels of TRIB3 in both colon
cancer, hepatocellular carcinoma (HCC), and lung cancer tumor tissues, when compared
with adjacent non-tumor tissues [67]. In agreement with the early studies, where TRIB3
transcript levels were evaluated, high TRIB3 protein levels were also found in SW480 cells,
and those were associated with TRIB3 mRNA expression [68]. Intriguingly, it was found
that two TRIB3 spliced isoforms were overexpressed in colon tumors [69]. The alterna-
tively spliced transcripts uc002wdm/NM_021158 and uc002wdn/AK297546 showed an
approximately 10- and 4-fold average increase, respectively, in colorectal cancer specimens,
compared to matched morphologically normal tissues [69].
According to these data, it is unquestionable that all members of the Tribbles family
are overrepresented in colon cancer and representative colorectal cancer cell lines (Table 1),
which might represent useful biomarkers for disease detection. However, it remains to be
investigated whether there is a correlation between TRIB1, TRIB2 and TRIB3 expression
in these samples. To the best of our knowledge, there are no studies where the authors
simultaneously analyzed two or more Tribbles in the same samples.
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Table 1. Tribbles amplification and overexpression in colon cancer tissues. Main result obtained for each study included
in the section is shown for each Tribble member. Details of the samples, databases and methodology used by the authors
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3. Clinical Significance of Tribbles Overexpression in Colon Cancer
To better understand the clinical impact of Tribbles pseudokinases overexpression in
patients with colon cancer, several clinical parameters and clinicopathological features were
analyzed and correlated to each member of the Tribbles family level in different samples.
With regards to TRIB1 and survival, one initial study did not find statistical differences in
survival between patients with or without TRIB1 (nor with MYC) gene amplifications [59].
However, a different study found that high (versus low) TRIB1 gene expression correlated
with poor survival in CRC patients [60]. Moreover, TRIB1 protein overexpression was
positively associated with distant metastasis and advanced staging [60].
For both melanoma and colon cancer patients, increased levels of TRIB2 gene ex-
pression correlated with a significantly worse clinical outcome, which was not observed
for pancreatic tumor patients [30]. In agreement, TRIB2 levels in colorectal cancer were
inversely correlated with survival rate of CRC patients, and positively correlated with
tumor grade [62]. Patients with high expression of TRIB2 experienced not only a worse
overall survival, as more recurrence [62].
A recent report analyzed the top ten most frequently mutated genes, which mutations
result in a disruptive protein structure [70]. From these, the authors identified the most
significantly upregulated genes which correlated with the worst survival outcome. Finally,
from these, they selected those genes which were theoretically druggable targets [70].
Using this elegant strategy, it was shown that the mRNA levels of TRIB2 (as well as of
DUSP4, dual-specificity MAPK phosphatase (4) were significantly higher in ACVR2A
mutant colon cancers compared to wild-type cases [70]. ACVR2A, which encodes activin
receptor type IIA, is a component of the TGFβ signaling pathway, shown to function
as a tumor suppressor gene in human CRC-derived organoids [71]. Though ACVR2A
mutations, reported in several cases of CRC [72], have been previously linked to earlier
tumor stages (stages I/II) [73], TRIB2 correlation to tumor staging was not performed
within this study [70]. In an independent clinical cohort, high TRIB2 expression was
associated with worse recurrence-free survival (RFS), and also linked to mutations in
ACVR2A gene [70].
In colonic premalignant polyps, TRIB2 expression was associated with an increased
risk for progression to colon cancer [74]. Along with phosphoinositide-3-kinase regulatory
subunit 3 (PIK3R3) and poly(ADP-ribose) polymerase-14 (PARP14) (among others), TRIB2
was up-regulated in sessile serrated polyps (SSA/Ps), while expressed at a lower level in
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both the right colon and hyperplastic polyps (HPs) samples [74]. Improved disease-free
survival (DFS), though not OS, were, however, previously described in colorectal patients
who expressed higher levels of PIK3R3 [75]. PARP14, by contrast, has been proposed as a
novel drug target for different types of cancer, though colon cancer not yet included [76].
Despite sharing histological similarities with the typical hyperplastic polyps (HPs) [77],
the SSA/Ps lesions are more prone to develop into cancer [78], which makes this finding
clinically relevant and proposes TRIB2 as a useful biomarker to early distinguish colonic
lesions [74].
TRIB3 expression was highest at Duke’s stages B > A (which represents stages with no
or infrequent dissemination) > C > D (representing more invasive and metastatic stages),
suggesting an inverse correlation between invasion and progression and TRIB3 expression.
Nevertheless, although the lowest level was observed in stage D, it was still much higher
than in normal colorectal epithelium [64]. Such as for TRIB1 [60], metastasis (M0/M1) was
correlated with TRIB3 expression [66]. However, metastatic sites, tumor size, invasion,
lymph node metastasis or lymphatic and venous invasion, were not significantly correlated
with TRIB3 levels [66]. Higher expression of TRIB3 was inversely correlated with overall
survival rate in two independent studies [66,67]. Unquestionable, high TRIB3 expression
levels correlated with low survival rates and poor outcomes of patients with CRC [79].
Recently, two independent predictive models included TRIB3 expression levels [80,81].
The analysis of the association between differentially expressed genes and overall survival
in a set comprised with 347 colon (but not rectal) cancer patients with a follow-up time
greater then 90 days, from TCGA dataset, identified TRIB3 as a high-risk RNA, along
with BDNF, KLF4, SESN2 and SMOC1 [80]. Based on the significant correlation of the 5
genes expression with tumor status and tumor stage, the authors developed a predictive
multi-mRNA-based model for overall survival, assigning risk scores to each patient and
obtaining a prognosis tool, aiming treatment optimization for patients [80]. These results
reinforced the usefulness of TRIB3, though combined with other genes, as a potential
prognostic biomarker for colon cancer. On the other hand, TRIB3 was associated, together
with other immune-related genes such as CHGA, LGALS4, LEP, NOX4, IL17A, HSPD1,
and CASP7, with colon cancer prognosis [81]. Based on the gene expression profiles,
the authors developed a molecular classifier tool. It was validated in 277 samples from
TCGA dataset that had available both gene expression and survival status and time, and in
an independent validation dataset (213 colon cancer samples from GEO). Alongside the
analysis of the tumor-infiltrating immune cells in colon cancer, a novel predictive tool for
colon cancer prognosis, which included TRIB3 levels, was established [81].
These results suggest a significant link between Tribbles expression and patient prog-
nosis (Table 2). Specifically, TRIB1 and TRIB3 might be considered candidates as predictive
markers of tumor metastasis development. Additionally, there is abundant data confirm-
ing the role of TRIB2 in drug resistance functioning as a predictive biomarker for drug
response. This is of utmost importance for the clinicians at the time of deciding the course
of treatments.
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Table 2. Clinical significance of Tribbles overexpression in colon cancer. Main results regarding the correlation between the
expression of each Tribbles family member and its clinical impact. Sample details, databases and methodology used by the
authors is detailed under the respective column.
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4. Tribbles Gene and Protein Expression Regulation in Colon Cancer
Recognizing how Tribbles are regulated in colon cancer is indispensable to better un-
derstand the physiopathology of this type of cancer and Tribbles involvement in the disease
development and progression. While for TRIB1, gene amplification might partially support
its increased levels not only in colon, but also in other types of cancer [82,83], the mecha-
nism behind TRIB2 overexpression in colon cancer patients is still unclear. In other tumor
types, however, different mechanisms for TRIB2 regulation have been described [41,84].
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For instance, while Wnt signaling regulated TRIB2 in hepatic cancer HepG2 cells, it had
no effect in the LS174T CRC cell line [41]. This might reflect that different transcriptional
programs are being differentially activated in different cancer types. By contrast, TRIB3
expression was induced in CRC cells after β-catenin activation by Wnt3a, in a dose- and
time-dependent manner. Conversely, decreased TRIB3 expression was observed in re-
sponse to β-catenin depletion [79]. The authors recognized TRIB3 as a transcriptional
target of the β-catenin–TCF4 complex and identified a TCF4-binding site (CACAGCTGCG
motif) at the C-terminal domain of the TRIB3 promoter region [79] (Figure 2). Moreover,
β-catenin inhibited TRIB3 degradation, contributing to the overall increased levels of
TRIB3 in CRCs by inducing its protein stability [79]. Additional mechanisms might be
involved in TRIB3 regulation in CRC. In HT-29 colorectal adenocarcinoma cells subjected
to hypoxia, TRIB3 was upregulated at the transcript and protein level [63], suggesting
TRIB3 could be regulated in CRC by classical hypoxia-related transcription factors, such as
HIF1α (Figure 2). More recently, it was shown that TRIB3 was up-regulated concomitantly
to the induction of C/EBP-homologous protein (CHOP) in HCT116 cells, while down-
regulated following CHOP knockdown [85,86], revealing TRIB3 being downstream of
CHOP-activated pathways (Figure 2), as previously proposed [87,88]. In addition, insulin
and IGF-1 induced TRIB3 protein expression in human colon cancer HCT-8 cells (Figure 2),
as well as in hepatoma HepG2 and lung cancer A549 cell lines [67]. Interestingly, other
C/EBP proteins have been linked to the oncogenic role of Tribbles proteins in myeloid
cancers [89].
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5. Tribbles Pharmacological Modulation in Colon Cancer
Genes that are over-expressed in cancer are more likely to be putative pharmacolog-
ical targets [90]. Tribbles proteins have emerged as interesting novel therapeutic targets,
with their unique pseudokinase domain providing a potential opportunity for drug de-
sign approaches [91,92]. To the best of our knowledge, there is lack of studies in colon
cancer patients that identified Tribbles differential expression in response to approved
cancer treatments.
Recent work demonstrated that afatinib, an approved irreversible electrophilic co-
valent EGFR/HER2 inhibitor for lung cancer treatment, increased TRIB2 degradation in
human acute myeloid leukemia (AML) cancer cells [93], demonstrating for the first time
that TRIB2 might be a druggable protein. Early this year, others showed similar results in
human hepatoma cell lines, where afatinib treatment (10 µM, 20 h) reduced TRIB2 protein
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levels and decreased cellular viability over 50% [94]. In SW-48, Colo205 and HT-29 CRC
cell lines, though Tribbles levels were not investigated, afatinib treatment (1 or 10 µM, 48 h)
also reduced cell viability [95], representing an opportunity for further studies, in order to
establish TRIB2 targeting as a potential strategy for treating colon cancer.
Regarding TRIB3, for which more studies have been performed, potential TRIB3
druggability has been suggested, although not yet fully validated in the CRC setting.
A study that analyzed different cell lines from the NCI60 database (using CellMiner),
representing cancer types that typically receive treatment with erlotinib, such as breast
cancer, colon cancer and NSCLC, identified TRIB3 at the top three genes that showed the
strongest correlation with EGFR inhibition [96]. The average expression of the seven genes
identified (LCN2, MET, MMP7, PTPRZ1, TRIB3, UGT1A6 and COL17A1 was lower in more
sensitive cells [96]. These results suggest that TRIB3 might be a useful clinical predictive
biomarker for erlotinib action in the absence of EGFR-activating mutations for colon cancer
patients. Conversely, high expression of TRIB3 could be related to CRC resistance to anti-
EGFR therapies, and future research should clarify this potential relationship. Interestingly,
it was recently shown that increased levels of TRIB3 were associated with elevated EGFR
stability and signaling activity in lung cancer, suggesting that the disruption of the TRIB3-
EGFR interaction could be a novel therapeutic target [97]. Nevertheless, whether TRIB3
might be in fact a downstream erlotinib therapeutic target still remains to be elucidated.
Another study showed that transcript and protein levels of TRIB3 were upregulated in
SW620 cells treated with the bioactive chemical modified fatty acid (FA) analog saturated
3-thia FA tetradecylthioacetic acid (TTA), compared to non-treated cells [98]. TTA not only
inhibited the growth of colon cancer cells, but also induced the expression of several other
genes involved in endoplasmic reticulum (ER) stress and unfolded protein response (UPR),
such as CHOP and C/EBPβ, whereas Cyclin D1 was down-regulated [98]. After treating
HCT116 cells with the photosensitizer hypericin and photodynamic therapy (HY-PDT) [99],
at the higher concentration range, TRIB3 protein levels were induced, along with induction
of CHOP, activation of the autophagy signal and cell death [85]. Nevertheless, TRIB3
up-regulation was CHOP-dependent, reflecting a most likely indirect action of HY-PDT in
TRIB3 modulation [85]. Importantly, TRIB3 has been previously located downstream of
CHOP-mediated pathways [87]. Similarly, after treatment of HCT116 cells with a specific
extract from Antrodia cinnamomea, a native Taiwanese rare mushroom, TRIB3 transcript
levels were induced in a dose-dependent manner [86]. Though CHOP itself was also
up-regulated, none of the other downstream genes of the apoptosis and autophagy CHOP-
mediated pathways were affected. Interestingly, this extract (ACF2) inhibited cellular
viability in different human colorectal cancer cell lines such as HCT116, HT29, SW480,
Caco-2 and Colo205 [86]. Though the authors validated that ACF2 inhibited the growth
of CRC cells subcutaneously inoculated into athymic nude mice, the levels of TRIB3 were
not evaluated in the tumors [86]. In both primary CRCs and HCT-8 ileocecal adenocarci-
noma cells, a fusion peptide named P2-T3A6, which inhibited cell viability and migration,
demonstrated having binding affinity with TRIB3. As a result, TRIB3 protein degradation
was accelerated, together with inhibition of TRIB3 gene transcription [79]. Interestingly,
P2-T3A6 peptide caused disruption of the β-catenin–TRIB3 interaction, though it did not
affect other TRIB3 known interactions, such as with SMAD3 [100], p62 [67] or AKT [31],
which might reflect an indirect peptide action on TRIB3 regulation by β-catenin [79], as
previously described above. Though there is few evidence regarding pharmacological
modulation of TRIB3 in CRC, all cases most likely represent an indirect effect through
β-catenin or CHOP pathways (Figure 3).
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6. Genetic Modulation of Tribbles in Colon Cancer
It is challenging to distinguish between driver and passenger mutations. Reports on
genetic alterations of Tribbles genes in human cancer are rare. A recent study described a
novel fusion transcript derived from a chromosomal translocation between the TRIB2 and
the PRKCE genes, in pulmonary carcinoid tumors [101]. Nevertheless, to the best of our
knowledge, no Tribbles mutations have been associated with CRC so far.
The first report on the effect of TRIB1 downregulation in colorectal cancer cells was
published in 2014, and showed that interfering with TRIB1 (cells stably transfected with
shRNA vectors, specifically knocking down TRIB1 gene expression) led to the decrease of
the number of double-minute chromosomes (DMs) formed, along with genomic instability
and cytotoxic DNA damage in the NCI-H716 tumor cells [56]. Although not specifically
tested for TRIB1, the authors showed that downregulation of other DM-carried oncogenes
amplified along the same chromosome, such as MYC and FGFR2, led to impairments
of cellular proliferation and invasion, suggesting a parallelism with TRIB1 [56]. TRIB1
stable or transient overexpression in SW480 and LoVo cells, respectively, showed enhanced
migratory and invasion ability of the cells, compared with controls [60]. Moreover, SW480-
TRIB1 cells exhibited increased metastasis capacity, evaluated in vitro by cell adhesion to
extracellular matrix (ECM) assays [60]. Conversely, silencing TRIB1 expression by shRNA
against TRIB1, in both SW480-TRIB1 and COLO320HSR cells, reduced the level of cell
migration and invasion [60], establishing a role for TRIB1 in colon cancer cells motility.
Similar to the findings previously described for TRIB1, siRNA down-regulation of
TRIB2 in SW48 and LoVo CRC cells suppressed proliferation, induced cell cycle arrest
(increased G0/G1-phase ratios along with reduced the S-phase ratios) and promoted
cellular senescence [62]. Although cell growth was affected, TRIB2 knock-down did not
induce apoptosis. The role of TRIB2 in the cancer progression phenotype was further
confirmed in these cells, since both proliferation and cell cycle progression were accelerated
by TRIB2 overexpression, along with decreased rates of cellular senescence [62].
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In 5 different CRC cells (DLD-1, LoVo, HCT116, KM12SM and SW480), TRIB3 knock-
down was obtained by siRNA [66]. For all cell lines, silencing of TRIB3 correlated with
decreased cellular proliferation. A very robust effect was observed at day 4 after plating,
mainly in DLD-1, LoVo, and HCT116 TRIB3-depleted cells [66]. The first in vivo experiment
regarding Tribbles cellular genetic manipulation was reported in 2015, where the authors
aimed to evaluate the role of TRIB3 in CRC tumorigenesis [67]. Genetically diabetic KK-Ay
mouse, a model of human T2D, showed not only higher TRIB3 expression in the liver
and lungs, but also the xenografted tumors from the diabetic model displayed elevated
TRIB3 expression, when compared with C57BL/6 mice [67]. After being inoculated in
BALB/c nude mice, TRIB3 knock-down in HCT-8 CRC cells led to decreased metastasis
and growth, revealing an antitumor role of TRIB3 silencing. A coincident TRIB3-dependent
phenotype was observed for human hepatoma HepG2 cells [67]. These results might
be particularly important for T2D patients, who are at greater risk to develop liver or
colorectal cancers [102]. The first in vivo modulation of TRIB3 was reported in 2019.
Few years later from previous report, the same research group down-regulated TRIB3
expression in C57BL/6J-ApcMin/J mice fed a high-fat diet (Trib3-KD), aiming to specifically
explore the role of TRIB3 in intestinal tumorigenesis [79]. Despite no differences in weight
changes between groups, Trib3-KD mice revealed higher survival rate and no colon or
small intestinal tumors at the 10 weeks of age time point. By contrast, 75% and 50% of
control mice developed tumors within their colons and small intestines, respectively [79].
Interestingly, mice overexpressing TRIB3 (TRIB3-OE) showed a slower increase in the
high-fat diet-induced body weight gain, despite the shorter colon length. As anticipated,
TRIB3-OE mice showed a heavier tumor burden, reflected by a decrease in respective
survival rates [79].
In colorectal cancer, the epithelial to mesenchymal transition (EMT) is associated with
a more invasive or metastatic phenotype, as cells show increased motility (mesenchy-
mal properties), while losing their epithelial characteristics [103]. A very recent report
showed that down-regulating TRIB3 in different colon carcinoma cell lines, such as SW480,
HCT116, CaCO2, SW48 and SKCO1, led to a mesenchymal-epithelial transition (MET)
phenotype [104].
It is evident that there is still much more to be learned about the role of these proteins
in the process of cancer progression. What we do know so far, is that the majority of the
reports pinpoint Tribbles as oncogenes in several cancer types, including colon cancer
(Table 3). This suggests that modulation of Tribbles protein levels might have a positive
impact delaying the oncogenic process. It is still to be determine if down-regulation of each
Tribbles protein individually would trigger a positive feedback on any of the other Tribbles.
Table 3. Tribbles genetic modulation response in colon cancer. Main results obtained for cellular genetic manipulation of
Tribbles is described, separately for either up- or down-regulation, and respective reference (author, year). Not applicable
(na) is shown when the data was not available.
Tribbles Genetic Manipulation Author, Year (Reference)
Up-Regulation Down-Regulation
TRIB1 na
Decrease in DM formation; genomic instability;
cytotoxicity (NCI-H716 cells). Ji, 2014 [56]
Increased migration, invasion and
metastatic capacity (SW480 and
LoVo cells).
Reduced migration and invasion (SW480-TRIB1
and COLO320HSR cells). Wang, 2017 [60]
TRIB2
Decreased cellular senescence,
increased proliferation and cell
cycle progression.
Decreased proliferation, induced cell cycle arrest
and cellular senescence (SW48 and LoVo cells) Hou, 2018 [62]
TRIB3
na Decreased proliferation (DLD-1, LoVo, HCT116,KM12SM and SW480 cells). Miyoshi, 2009 [66]
na Decreased metastasis and growth (HCT-8 cells innude mice). Hua, 2015 [67]
Decreased survival rate and
tumor burden (TRIB3-OE mice).
Increased survival rate, no colon tumor
development (Trib3-KD mice). Hua, 2019 [79]
na Mesenchymal-epithelial transition phenotype(SW480, HCT116, CaCO2, SW48 and SKCO1 cells).
Makino, 2020 [104]
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7. Downstream Mechanisms Regulated by Tribbles in Colon Cancer
A better understanding of the downstream pathways, potentially regulated by Tribbles
proteins, is essential to better direct the therapeutic options available, based on Tribbles
expression and the mechanism of action involved. Though an association does not always
reflects causation, analyses from tissue microarray consisting of 118 Dukes’ A and B CRC
patients revealed a significant correlation of TRIB1 protein expression with ERK signaling
pathway activation, and AKT and MYC protein abundance [59]. In agreement, TRIB1
overexpression (TRIB1-OE) in SW480 cells also increased ERK, as well as Src and FAK (focal
adhesion kinase), protein phosphorylation [60]. In addition, TRIB1 overexpression led to
up-regulation of MMP-2 and MMP-9 proteolytic enzymes protein levels. Conversely, RNA
interference TRIB1 silencing in TRIB1-OE cells fully reversed the previous phenotype [60].
Moreover, specific ERK, Scr and FAK inhibitors independently down-regulated MMP-2
(but not MMP-9) expression in TRIB1-OE cells [60].
In TRIB2 knocked-down SW48 and LoVo cells, increased p21 protein and mRNA
was observed, while p53 (in contrast with previous report in a different cancer type, ie,
melanoma [30]), cyclin D1 or p16 levels remained unchanged [62]. Conversely, overexpres-
sion of TRIB2 showed the inverse phenotype (i.e., decreased p21), in a p53-independent
manner. The authors demonstrated TRIB2 negatively regulated p21 at the promoter level,
through TRIB2 kinase-like domain binding and cooperation with AP4, which was elevated
in CRC tumor compared with the corresponding normal tissues [62]. Though TRIB2 did
not directly influence AP4 expression, upon TRIB2 over-expression, AP4 protein was fur-
ther enriched at the p21 promoter [62]. The observed cellular events were validated in
a CRC xenograft nude mice in vivo model, subcutaneously injected with stable TRIB2-
knockdown SW48 cells, where p21 expression levels were significantly increased, compared
to controls [62].
TRIB3 has been previously described, in other cellular types, to negatively regulate
Akt-mTOR pathway by direct binding to AKT and consequent dephosphorylation [31].
In agreement, depletion of TRIB3 in HCT116 cells reversed the reduction of phospho-Akt
and phospho-mTOR in response to A. cinnamomea-derived extract ACF2 treatment [86].
Intricately, TRIB3 silencing also decreased ACF2-induced LC3-II levels [86]. Making use of
bioinformatic analysis, Hua et al. identified an enrichment of the Wnt signaling gene set in
TRIB3-overexpressing cells in patients with CRC [79]. Experimentally, the authors verified
that β-catenin transcriptional activation correlated with TRIB3 levels in different CRC
cell lines. Moreover, when comparing tumor with adjacent normal tissues, higher TRIB3
and β-catenin expression, along with proteins co-localization, was observed. By contrast,
colon tissues from TRIB3-KD mice showed much lower expression of genes regulated
by Wnt signaling to β-catenin, compared to control mice, such as Axin2, c-Myc, Cyclin
D1, and TRIB3 itself. TRIB3 and TCF4 were shown to interact, while depletion of TRIB3
decreased the formation of the β-catenin-TCF4 complex. Finally, it was demonstrated that
the up-regulation of these genes regulated by Wnt, in response to TRIB3 overexpression,
was β-catenin dependent, as cellular β-catenin depletion reversed the phenotype [79]. In
the context of colon cancer, all three Tribbles seem to induce signaling pathways that are
commonly associated with tumor progression.
8. Conclusions and Future Perspectives
There has been accumulating evidence that all members of the Tribbles family play
a role in tumorigenesis. Whether they contribute to cancer progression or impairment is
still an open question. This review highlights the existing research on the contribution
of TRIB1, TRIB2 and TRIB3 to colorectal cancer as well its potential as biomarker for
disease progression and/or prognosis. There is now accumulating data that TRIB2 acts
as an oncogene in several tumor types, including colon cancer. This is not as clear for
TRIB3, as it was found that TRIB3 overexpression negatively regulates the mTOR pathway,
which is hyperactivated in several tumor types. On the contrary, different studies show
that TRIB3 overexpression is positively correlated with poor prognosis and survival of
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colon cancer patients, highlighting the potential of using TRIB3 as a predictive biomarker.
These data suggests that Tribbles family members role might be cell context dependent.
Moving forward, it will be important to thoroughly study the interaction of all family
members as they might have redundant roles in specific contexts. The generation of in vivo
knock-out models using CRISPR technology would certainly contribute to decipher the
role of each Tribble isoform in CRC development. On the other hand, colon cancer stem
cells (CCSC) have been associated with patient relapse and chemoresistance, with diverse
molecular mechanisms involved [105]. Importantly, high Tribbles levels have been linked
with quiescent stem cell population, at least in hematopoietic diseases [106]. Thus, it is
of great interest to understand the role of this family of proteins in the maintenance of
CCSC and how they contribute to drug resistance. Furthermore, as new data emerge
suggesting that this family of pseudokinases might be therapeutically modulated, it is of
outmost importance to thoroughly understand the mechanisms by which these proteins are
governed. This will potentiate the development of novel pharmacological approaches or
the repurposing of existing drugs that specifically target the Tribbles proteins and improve
patient care.
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